EURO
34,81
DOLLAR
32,53
BIST
9.732
GOLD
2.427,13
Adana
Adıyaman
Afyon
Ağrı
Aksaray
Amasya
Ankara
Antalya
Ardahan
Artvin
Aydın
Balıkesir
Bartın
Batman
Bayburt
Bilecik
Bingöl
Bitlis
Bolu
Burdur
Bursa
Çanakkale
Çankırı
Çorum
Denizli
Diyarbakır
Düzce
Edirne
Elazığ
Erzincan
Erzurum
Eskişehir
Gaziantep
Giresun
Gümüşhane
Hakkari
Hatay
Iğdır
Isparta
İstanbul
İzmir
K. Maraş
Karabük
Karaman
Kars
Kastamonu
Kayseri
Kırıkkale
Kırklareli
Kırşehir
Kilis
Kocaeli
Konya
Kütahya
Malatya
Manisa
Mardin
Mersin
Muğla
Muş
Nevşehir
Niğde
Ordu
Osmaniye
Rize
Sakarya
Samsun
Siirt
Sinop
Sivas
Şanlıurfa
Şırnak
Tekirdağ
Tokat
Trabzon
Tunceli
Uşak
Van
Yalova
Yozgat
Zonguldak
Kıbrıs
Famagusta
Girne
Güzelyurt
Lefkoşa
21
°
HOMEPAGE
SINGUP
SINGIN
ANALYSIS
BROKERS
BUSINESS
CRYPTOS
EVENTS
INVESTING
POLITICS
TRADING
Search
WORLD
"Laboratorios Rovi" Search Results
Rovi receives approval in the US to market a drug as a treatment for schizophrenia in adults
Rovi hires Lazard for the possible sale of its manufacturing business to third parties
Rovi earns 170 million in 2023, 15% less, and announces a dividend of 1.10 euros per share
The Ibex 35 falls 0.65% at midday and loses 10,100 points weighed down by Rovi (-10%)
Rovi earns 66.6 million until June, 17% less, and starts a share buyback program
Fluidra, Rovi, Dominion and Gestamp distribute dividends this Wednesday
Rovi will distribute a dividend of 1.29 euros gross per share on July 5
The Ibex 35 deepens its fall towards the half session and is heading for 9,200 points
Rovi earns 200 million in 2022, 30% more, exceeds its income forecast and will pay a dividend of 1.29 euros
Rovi will increase its revenues between 5% and 10% in 2023 compared to 2021 and reinforces collaboration with Moderna
Rovi leads the losses of the Ibex 35 with a drop of more than 7%
Rovi raises its net profit by 23% in the first nine months, to 121.5 million